Dogwood Therapeutics, Inc. Financing Receivable, Credit Loss, Expense (Reversal)
Dogwood Therapeutics, Inc. (DWTX) reported Financing Receivable, Credit Loss, Expense (Reversal) of -$15.02 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProvisionForLoanLossesExpensed · last filed 2022-03-18
- Dogwood Therapeutics, Inc. financing receivable, credit loss, expense (reversal) for the quarter ending 2020-12-31 was $0.00.
- Dogwood Therapeutics, Inc. financing receivable, credit loss, expense (reversal) for the quarter ending 2020-09-30 was $0.00.
- Dogwood Therapeutics, Inc. financing receivable, credit loss, expense (reversal) for the quarter ending 2020-06-30 was -$15.12K.
- Dogwood Therapeutics, Inc. financing receivable, credit loss, expense (reversal) for the quarter ending 2020-03-31 was $100.00.
- Dogwood Therapeutics, Inc. financing receivable, credit loss, expense (reversal) for fiscal 2020 was -$15.02K.
| Period end | Financing Receivable, Credit Loss, Expense (Reversal) 3 month | Financing Receivable, Credit Loss, Expense (Reversal) 6 month | Financing Receivable, Credit Loss, Expense (Reversal) 9 month | Financing Receivable, Credit Loss, Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | -$15.12K derived: sum of 3 quarters · filed 2022-03-18 | -$15.02K 10-K · filed 2022-03-18 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$15.12K derived: sum of 2 quarters · filed 2021-11-12 | -$15.02K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$15.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$15.02K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $100.00 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |